“I look forward to assisting Theralase achieve its strategic objectives of commercialization through partnering of its lead pharmaceutical drug with large pharmaceutical organizations in North America and internationally,” Dr. Lbiati said in a statement.
She said Theralase’s anti-cancer therapy is on the “verge of demonstrating to the world the safety and efficacy that this platform truly brings to patients inflicted with cancer, firstly, for patients diagnosed with Bacillus Calmette-Gurin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC), who are running out of therapeutic options and are facing bladder removal surgery.”
Matthew Perraton, chairman of Theralase, said Dr. Lbiati possesses a wealth of international experience across all aspects of drug development from clinical research to medical affairs, marketing to commercialization of various drug candidates.
“Her expertise comes at an opportune time, as we have made great strides in our Phase 2 BCG-Unresponsive NMIBC clinical study (Study II), whose strong interim clinical data verifies that light-activated Ruvidar is a potent photodynamic compound (PDC) that is capable of destroying high-grade bladder cancer and providing a durable response to this disease, while providing a very high safety profile for the treated patient,” Mr. Perraton said
Based on the latest interim clinical data, he said Theralase is commencing to actively explore international partnering, licensing and distribution opportunities for its cancer targeting PDC, Ruvidar.
Theralase appoints internationally accomplished biopharma Executive, Dr. Kaouthar Lbiati, as independent board director - BioTuesdays